

# Drug utilisation data sources in the EU.

D Prieto-Alhambra, MD MSc PhD



making the difference in medication

## **CONFLICTS OF INTEREST**

- I have received unrestricted research grants from AMGEN Spain and BIOIBERICA.
- I have been involved in Advisory Boards for AMGEN.
- No other conflicts of interest.



- To identify and access a number of publicly available online EU drug utilisation data sources
- To estimate DDDs / 1000 inhabitants use of a certain medication or group of medications
- To discuss the relevance of populationbased drug utilisation data



- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK



- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK





#### AVAILABLE DATABASES IN THE EU: PROTECT: WP2, WG3

#### APPENDIX 5. SUMMARY TABLE OF NATIONAL DRUG CONSUMPTION DATABASES

	DENMARK (Danish National Prescription Database) The Danish Medicines Agency (Free online) www.medstat.d k/MedStatData Viewer.php	FRANCE (ERASME) Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (Application) www.ameli.fr	FINLAND (Prescription register database) Social Insurance Institution	GERMANY Wissenschaftliche s Institut der AOK (Research Institut of the AOK) (Application) www.wido.de	ITALY (OsMED database) Italian Medicine Agency. Osservatorio sull'impiego de medicinali (Application) www.agenziafa aco.gov.it	NORWAY (Norwegian Prescription database) es Norwegian Institute of Public Health ei <u>(Free online)</u> <u>www.norpd.n</u> <u>O</u>
	NETHER GIP database	LANDS SFK database	POLAND NHF database	SPAIN	SWEDEN (The Swedish Prescribed Drug Register)	UNITED KINGDOM (ePACT database)
Data provider (accessibility) Web site	Health Care Insurance Board (Free online) www.gipdatab ank.nl	Poundation for Pharmaceutical Statistics (Application) www.sfk.nl	(Application)	Department of Pharmacy and Health Products (Application) www.aemps.es	Ine National Board of Health and Welfare (Free online) http://192.137.16 3.49/sdb/lak/val. aspx	NHS Prescription Services (Application) www.epact.net



- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK



#### **DATA IN**





#### DATA OUT





- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK



### CALCULATING DDDs/1,000 persons/day

- WHO: DDDs/1000 inhab/day are the gold standard of drug consumption.
- Rough estimate of the proportion of the population treated on a given day.
- E.G.: 10 DDDs/1000 inhabitants/day for drug A in region X indicates that on average 1% of the population from region X gets treatment with A daily.



#### CALCULATING DDDs/1,000 persons/day (2)

## DDDs used in a year x 1000 DDDs/1000/d = Population x 365



- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK



#### USES OF DDD/1000/d DATA

- Drug utilization description/comparison<sup>1</sup>
- Denominator for adverse drug reaction rates<sup>2</sup>
- Screening for problems in drug utilization<sup>3</sup>
- Monitoring the effects of regulatory and informational activities<sup>4</sup>
- Estimating prevalence of drug use for PARs<sup>5</sup>



1.Bergman U et al. Clin Pharmacol Ther 1991 2.Bergman U et al. Br Med J 1978 3.Westerholm B et al. Br J Clin Pharmacol 1986 4.Schussel K et al Pharmazie 2006 5.Prieto-Alhambra D et al. Osteoporos Int 201415

#### **DESCRIBING DRUG UTILIZATION**



#### Figure I

The ns-NSAID and COX-2 inhibitor prescription pattern in concession beneficiaries in Australia and in Queensland between 1997 and 2003.



Barozzi N et al. BMC Health Services Res 2008

#### **COMPARISON OF DRUG UTILIZATION**



#### Total COX-2 Selective Inhibitor Dispensing In Rural and Urban Queensland



Behan K et al. Eur J Clin Pharmacol 2005

#### MONITORING THE EFFECTS OF REGULATORY ACTIVITIES AND GUIDELINES



Basic analgesics, very strong analgesics no change in trend



Bedson J et al. Eur J Pain 2012

#### MONITORING THE EFFECTS OF REGULATORY ACTIVITIES AND GUIDELINES(2)





Bedson J et al. Eur J Pain 2012

#### FAST "REPLICATION" IN DK DATABASE





Bedson J et al. Eur J Pain 2012

#### **ADVANTAGES AND PITFALLS**

Rapid response (eg secular trends)
International comparison
Comparing the "effect" of different drugs DDD is not necessarily the prescribed dose
Estimated for adults (not for children)
Does not account for adherence



- Breadth of routinely collected data in the EU: DU databases
- DU databases: DATA IN, DATA OUT
- Estimating DDDs/1000 persons/day
- Uses of population drug utilization data
- Advantages and pitfalls of DDD/1000/d
- EG: Alendronate in Norway and DK



#### DANISH MEDSTAT: SEARCHING FOR ALENDRONATE USE (DDDs/1,000/day)

#### MEDSTAT.DK

Home Groups of medicines C ATC code C Product name	© Data basis and descrip	otion
1 ATC code	C 🕖 Year C 🕖 Region	C
M05BX03	2013 Entire Denmark	
M (Musculo-skeletar system)	- 2012 Hovedstaden	
M01 (Antiinflammatory and antirheumatic products)	2011 Nordjylland	
M02 (Topical products for joint and muscular pain)	2010 Midcjylland	
M03 (Muscle relaxants)	2008 Syddanmark	
M04 (Antigout preparations)	Conder C Age group (change)	
M05 (Drugs for treatment of bone diseases)	U Gender U Age group ( <u>change)</u>	
M05B (Drugs affecting bone structure and mineralization)	Gender, combined 10 - 14 y.o.	
M05BA (Bisphosphonates)	Male 15 - 19 y.o.	
··· M05BA01 (Etidronic acid)	Female 20 - 39 y.o.	
M05BA02 (Clodronic acid)	65 - 79 v o	
··· M05BA03 (Pamidronic acid)	80+ y.o.	
M05BA04 (Alendronic acid)	A Sector	0
m M05BA06 (Ibandronic acid)	5000	<u> </u>
M05BA07 (Risedronic acid)	Primary sector	
M05BA08 (Zoledronic acid)	Hospital sector	
MOSBB (Bisphosphonates, combinations)	local	
MOSBC (Bone morphogenetic proteins)	a Search variable	0
MOSBX (Other drugs anecting mineralization)	J Search variable	
MOSBX03 (Scioncium raneiace)	Volume sold	
M00 (Other drugs for disorders of muscule skeletal syst)	volume sold per 1,000 inhabitants per day	
D (Antiparasitic products, insecticides and repellants)		
R (Respiratory system)		
	Show result Show result in Exc	el



-M05BA04 -2009-13 -40-64y -Volume per 1,000 inhab. per day



#### DANISH MEDSTAT DATABASE : RESULTS FOR ALENDRONATE USERS

## MEDSTAT.DK

ATC code: M05BA04

Search variable: Volume sold per 1,000 inhabitants per day

Sector: Total

Region: Entire Denmark

	2009	2010	2011	2012	2013	
Total sales	Volume sold (DDD) per 1,000 inhabitants per day					
M05BA04 (Alendronic acid)	9.3	10.6	11.7	12.4	12.7	



#### **NORWEGIAN PRESCRIPTION DATABASE**

folkehelseinstituttet				
Home page Prescription Database				
Statistics from the Norwegian Pr	escription Database			
Select drugs using drug categories 🗈 —ADHD, drugs used for	Unit of measurement 🗈	Age <sub>i</sub> Ch All ages	eck all Clear	
Analgesics excluding opioids Analgetics	□Users per 1000 inhabitants	0 - 4 5 - 9		
Antibacteriais Anti-dementia drugs	Turnover by dosage	10 - 14 15 - 19	heck regions /	DDDs per
Select drugs using the ATC-system	(DDD)	Residence C	ounties Clear	
B Blood and blood forming organs     C Cardiovascular system	Period I       LEntil         2013       Hea         2012       Hea         2011       Hea         2010       Aker         2009       Aust         2008       Bust	Health region Nor	t-Norge d-Norge	1000/day is
Dermatologicals		Health region Vest	-Øst t	
<ul> <li>Genito urinary system and sex</li> <li>hormones</li> <li>Systemic hormonal preparations, excl.</li> </ul>		Akershus Aust-Agder Buskerud		not one of the
	2006 2005 2004	- Financania		units available
	Sex i	-		
	□Both sexes □Women □Men			
Select drugs by product name and/or active ingredient		Show report in Excel		
Active ingredient Product name Search		Clear		
european association of hospital pharmacists				



#### DDDs used in a year x 1000

#### DDDs/1000/d =

Population x 365



#### NORPD: ESTIMATING ALENDRONATE USE (DDDs/1,000/day)

folkehelseinstituttet					
U Home page Prescription Database					
Statistics from the Norwegian Pre	escription Database				
Select drugs using drug categories	Unit of measurement 🗉	Age	Check all	Clear	-M05RA04
□ADHD, drugs used for	Number of users	✓All ages			-1V103D/10-T
Analgesics excluding opioids	jusers per 1000	_0 - 4 □5 - 9			
Antibacterials	✓Population base	<b>10</b> - 14			-2009-13
□Anti-dementia drugs	Turnover by value	015 - 19		. ,	
Select drugs using the ATC-system	(DDD)	Residence	Check reg counties	ions / Clear	
MOSBA01 Etidronic acid	Period i	Entire country	Midt Noveo		-40-64v
M05BA02 Clodronic acid	<b>2</b> 2013	Health region	Nord-Norge		
□M05BA03 Pamidronic acid	<b>√</b> 2012	Health region	Sør-Øst		-Turnover by
M05BA04 Alendronic acid	<b>√</b> 2010	Health region	Vest		i aino vei sy
M05BA05 Tiludronic acid	<b>1</b> 2009	Aust-Agder			dosage (DDD)
□M05BA06 Ibandronic acid	2008	Buskerud			(DDD)
	2006				Detation
	2005				-Population
	Sev i				1
	Both sexes				base
	Women				
	⊡Men				
Select drugs by product name and/or active ingredient		Show report in Exce	el		
Active ingredient Product name					
Search		Clear			
	·			1	
=////=eand					
european association					

#### NORPD: ESTIMATING ALENDRONATE USE (DDDs/1,000/day) (2)

#### Norwegian Prescription Database

					Population base	Turnover by dosage (DDD)
M05BA04	2009	All ages	Both sexes	Entire country	4 829 800	15 348 329
	2010	All ages	Both sexes	Entire country	4 888 946	15 538 122
	2011	All ages	Both sexes	Entire country	4 953 216	15 471 983
	2012	All ages	Both sexes	Entire country	5 018 414	15 278 523
	2013	All ages	Both	Entire country	5 080 148	15 176 424



#### NORPD: ESTIMATING ALENDRONATE USE (DDDs/1,000/day) (3)

Ć	Excel File E	dit View Ir	nsert Format To	ools Data W	indow 🐓 Help	1 million	- And	and the second second		🕴 🔶 🚟 98% 🕗 Wed 1
	0				👕 rapport-2_aln_	DDDs&basepopulation	_withDDDsper	L000day.xls		
2		X 🔓 🛱 🔞	🖌 🖄 • 🖾 • 🔰	• <b>A</b> • <b>F</b> • <b>(</b>	fx 🖭 📑 200% 🔹					Q- fracture
A 1	lome Layout	Tables C	harts SmartArt	Formulas I	Data Review					
	Edit	Fon	t	Aligr	nment	Number		Format		Cells
R.	Fill 🔻 Aria	۲ v	10 - A- A-	= = ab	c 🔻 📄 Wrap Text 🔻 Ge	neral 🔹	<	Normal Bad	Good	
Paste	⊘ Clear ▼ B	IU	• <u> </u>		Merge 🔹 📑	▼ % <b>&gt;</b> \$.0 \$.00	Conditional Formatting	Neutral	tion Check Cell	Insert Delete Format
1	SUM 😫 🚱	📀 (* fx =	H11*1000/(G11*365)							
_	A	B	C	D	E	F G	H	I		J
1	Norw	odian	Droccri	intion	Databa	0				
2		egian	FICSU	puon	Databas	SC				
3										
5										
	-									
9	-						_			
						Populat	ion Turi	nover by		
10		1				base	dos	age (DDD)		
	M05BA04	2009	All ages	Both	Entire country	4 82	9 800	15 348 329		
11				sexes					= <mark>H11</mark> *1000/(G11	*365)
		2010	All ages	Both	Entire country	4 88	8 946	15 538 122		
12		_		sexes						
		2011	All ages	Both	Entire country	4 95	3 <mark>21</mark> 6	15 471 983		
13				sexes						
		2012	All ages	Both	Entire country	5 01	8 414	15 278 523		
14				sexes						
		2013	All ages	Both	Entire country	5 08	0 148	15 176 424		
15				sexes						
	1									



#### NORPD RESULTS: ALENDRONATE USE (DDDs/1,000/day)

#### Norwegian Prescription Database

					Population base	Turnover by dosage (DDD)	
M05BA04	2009	All ages	Both	Entire country	4 829 800	15 348 329	
		-	sexes	-			8,706409466
	2010	All ages	Both	Entire country	4 888 946	15 538 122	
		-	sexes	-			8,70743863
	2011	All ages	Both	Entire country	4 953 216	15 471 983	
		U U	sexes				8,557873212
	2012	All ages	Both	Entire country	5 018 414	15 278 523	-
		0	sexes	· · · · · ·			8,341074914
	2013	All ages	Both	Entire country	5 080 148	15 176 424	
		5	sexes	,			8,184652068



#### TRENDS OF USE OF ALN IN DK AND NOR IN THE YEARS 2009-2013





# Drug utilisation data sources in the EU.





D Prieto-Alhambra, MD MSc PhD